Canada Drug Delivery Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (Inhalation Drug Delivery, Injectable Drug Delivery, Nasal Drug Delivery, Oral Drug Delivery, Transdermal Drug Delivery), And By Application (Treatment of diseases, Research/Academic Purposes) - Forecasts From 2022 To 2027

Description

The Canadian Drug Delivery Market is set to reach USD 34.562 billion in 2030, growing at a CAGR of 7.51% from a valuation of USD 16.746 billion in 2020.

Canada Drug Delivery Highlights

• Government investments boost biomanufacturing and life sciences innovation.
• Focus on non-invasive systems enhances patient convenience and adherence.
• Technological advances in nanotechnology improve targeted drug administration.
• Rising chronic disease management drives demand for advanced delivery solutions.

The Canadian Drug Delivery Market is expected to witness rapid growth, due to the increasing prevalence of chronic diseases, the rapid expansion of biologics and nucleic acid-based therapeutics, and the strong government support for domestic biomanufacturing. The market is increasingly characterized by a shift from oral drug formulations towards advanced delivery modalities such as lipid nanoparticles, long-acting injectables, implantable depot systems, transdermal patches, and self-administered device–drug combinations, which are indispensable for the next generation of high-value specialty pharmaceuticals.

Meanwhile, federal initiatives focused on making biomanufacturing more resilient are also helping top CDMOs and biotech companies to increase their capacity, thus enabling the US to produce complex biologics and novel delivery platforms locally. The elderly population, growing patient preference for care at home, and the trend towards personalized medicine are deepening the need for delivery devices that facilitate adherence, provide better targeting, and reduce the healthcare system's load.

Canada Drug Delivery Overview

The Canadian drug delivery market is undergoing gradual growth, mainly attributed to the increasing incidences of chronic diseases, ongoing investments in biopharmaceutical innovations, and the rapid transition to sophisticated delivery systems such as lipid nanoparticles (LNPs), sustained-release injectables, implantable devices, and targeted biologic delivery systems. The mature pharmaceutical manufacturing base in the country, supported by companies that specialize in sterile fill-finish, biologics processing, and formulation engineering, will not only consolidate but also broaden domestic capabilities, thereby reducing the dependency on foreign supply chains and enhancing the response to the public health needs.

Various government incentives, such as the Strategic Innovation Fund (SIF), the Biomanufacturing and Life Sciences Strategy, the National Research Council (NRC) Industrial Research Assistance Program (IRAP), and the selectively targeted federal–provincial biomanufacturing grants, are leading a large-scale biomanufacturing turnaround and local vaccine production initiative across Canada. Thus, this is the direct support of the expansion activities at CDMOs and biotech firms. As a result of these financing sources, companies can revamp sterile fill-finish lines, construct GMP suites for advanced modalities like mRNA and lipid nanoparticles, increase biologics fermentation and purification capacity, and speed up the commercialization of next-generation drug delivery platforms, thereby making Canada stronger as a whole in pharmaceutical manufacturing resilience.

The expansion of the drug delivery market is very much dependent on the patterns of drug purchases. In essence, as more sophisticated delivery platforms like lipid nanoparticles, long-acting injectables, and implantable are developed and made available to the market, they create a demand for high-end therapeutic products that are more effective, stable, and promote patient adherence. This, therefore, results in increased spending by healthcare providers, pharmacies, and patients. The total drug purchases in Canada in 2023 are estimated to have been around $43.5 billion, which is 13.7% higher than in 2022 (retail purchases: 12.9% growth; hospital purchases: 17.7% growth), according to the Canadian Journal of Health Technologies. The purchase in 2024 reached $47.25 billion.

The market has expanded, but it still experiences difficulties like the need for regulatory harmonization, increasing production costs, and competition from global CDMOs. The upward trend of the market is, however, anticipated to be strong during the forecast period due to Canada's continued investments in biopharma infrastructure and advanced delivery science.

The top key companies that are instrumental in the Canadian Drug Delivery Market include global leaders like Medtronic, AstraZeneca, Becton, Dickinson and Company, Boston Scientific Corporation, and Johnson & Johnson; in addition, the significant domestic and regional players such as Apotex Inc., Insulet Corporation, NurExone Biologics Inc., Rapid Dose Therapeutics Corp., and BioNxt Solutions, these are all the companies that are driving the Canadian ecosystem with their contributions to drug delivery technologies, device innovation, and pharmaceutical manufacturing capabilities.

________________________________________________________________

Canada Drug Delivery Drivers

Rising Burden of Chronic and Lifestyle Diseases

The increasing rate of chronic and lifestyle diseases largely influences the drug delivery market in Canada. These conditions include diabetes, cardiovascular disorders, cancer, respiratory diseases, and autoimmune illnesses, which lead to continuous demand for more effective, predictable, and patient-friendly therapeutic solutions. As the Canadian population ages and the obesity rate, sedentary lifestyles, and metabolic disorders rise, healthcare systems are transitioning to chronic disease management models that entail the need for ongoing medication regimens and high adherence rates. According to Diabetes Canada, the estimated prevalence of diabetes (type 1 + type 2 diagnosed + type 2 undiagnosed) is 5,805,000, or 15%, in 2024 and 7,304,000, or 16%, in 2034.

The rise of chronic diseases is pushing hospitals and pharmacies to change their inventories to include more high-value specialty drugs and biologics, which, in turn, is resulting in them having to depend more on sophisticated delivery technologies. Moreover, as a larger number of chronic patients are choosing home care and self-administration to avoid frequent clinical visits, the demand for auto-injectors, wearable injectors, and needle-free delivery systems is increasing rapidly. Together, the growing chronic disease burden is not only increasing the volume of drugs consumed in Canada but also causing a shift in market preference toward innovative delivery systems that improve efficacy, adherence, convenience, and long-term disease control.

________________________________________________________________

Canada Drug Delivery Segmentation Analysis

By Application: Oncology

Based on the application, the Canadian drug delivery market is segmented into oncology, neurology, diabetes, infectious disease, and others. Drug delivery has provided a next-level approach to achieve targeted delivery of therapies and medication, thereby improving overall patient outcome. Such benefits have accelerated the adoption of drug delivery in cancer treatment as it reduces overall system toxicity and improves therapeutic precision. Cancer is amongst the major causes of death in Canada, which is attributable to genetic and various life factors, hence the concerned authorities are investing in enhancing their diagnostic support & treatment services to address the unmet challenge.

According to the Canada Cancer Statistics Dashboard (CCSD), in 2025, the projected number of cancer cases was 2,54,800, representing a considerable growth of 3.1% over the projected figure for 2024. Likewise, the same source also specified that the most common cancer types, such as lung cancer, breast cancer, prostate cancer, and colorectal cancer, constitute nearly 48% of the total new cancer cases in the same year.

Drug delivery offers advancements that support nanotechnology and precision medicine, which, unlike traditional chemotherapy, minimizes healthy tissue damage. The ongoing advancement in medication, followed by the implementation of strategies to increase access to necessary medicine, has provided a framework for the development & adoption of drug delivery systems for cancer.

In October 2025, the Innovative Medicines Canada (IMC) announced the launch of the “Funding Accelerated for Specific Treatment (FAST) Program” that aims to deliver high-priority medicine, including cancer-related therapies, to patients. Likewise, on November 2nd 2025, the Canadian Cancer Society (CCS) launched the “2026-2035 Pan-Canadian Lung Cancer Action Plan” that aims to reduce lung cancer mortality by over 30% in the country.

Furthermore, market players are investing in the development of drug delivery products for cancer treatment, providing new growth prospects. For instance, BioNxt Solution’s “Targeted Chemotherapy Drug Delivery Platform” provides an innovative way of administering cytotoxic drugs with minimal healthy tissue damage. The platform is compatible with nearly 100 cytotoxic drugs and is designed to support a broader range of chemotherapy agents.

By End-user: Hospitals

Based on the end-user, the Canadian drug delivery market is segmented into hospitals, specialty clinics, and others. Technological advancement in hospitals and other healthcare centres is gaining traction in Canada, fuelled by the growing need to provide effective diagnostic services at a high precision rate. Likewise, the emphasis on reducing medication errors to improve patient safety has transformed the mode of administration. Drug delivery products, including infusion pumps, automated injectors and smart IV devices, fulfil the required criteria of modern medication, which is projected to drive their adoption in Canadian hospitals.

Moreover, the growing prevalence of major health issues such as diabetes, cancer, and other infectious diseases has also escalated the hospital caseloads, which is also driving the need for a reliable system for nutrient and necessary fluid delivery post-op management. According to Statistics Canada, nearly 3.8 million people, constituting 9.6% of Canada’s population, have diabetes. The same source also stated that 6% Canadian adults have prediabetes, which increases their chances of developing type-2 diabetes.

The high treatment cost in hospitals has also accelerated the demand for alternatives that meet patient’s treatment criteria, especially for major diseases like cancer. According to the Canadian Cancer Society’s “Canadian Cancer Statistics: A 2024 special report on the economic impact of cancer in Canada”, the average treatment cost, inclusive of out-of-pocket expenses, was $33,000. Such high cost, coupled with economic fluctuations, is anticipated to drive the development of drug delivery systems for precision cancer therapies in hospitals.

The ongoing integration of AI-infused products in medical applications, followed by the establishment of new hospitals and healthcare centres, is acting as an additional driving factor. On November 24th 2025, Hamilton Health Sciences (HHS) leaders announced the establishment of a new West Lincoln Memorial Hospital (WLMH), which expanded surgical capacity and emergency case space.

________________________________________________________________

Canada Drug Delivery Key Developments

• November 2025: Health Canada has approved a new LUPRON DEPOT® strength for the treatment of advanced prostate cancer.
• September 2025: Moderna declared that provinces and territories would receive the first mRNA vaccines produced entirely in Canada. This significant achievement improves national health security and increases Canada's capacity to produce vaccines domestically.
• April 2025: Health Canada has accepted the New Drug Submission (NDS) for AGAMREE®, a novel corticosteroid treatment for Duchenne muscular dystrophy (DMD), for review, according to a statement released by Kye Pharmaceuticals, Inc. (Kye).
• 2025: Medtronic plc revealed that it has filed 510(k) applications with the U.S. Food and Drug Administration (FDA) to obtain the go-ahead for an interoperable pump.

________________________________________________________________

Canada Drug Delivery Segmentation:

• By Device Type
  • Inhalers
  • Autoinjectors
  • Infusion Pumps
  • Patches
  • Others
• By Mode of Administration
  • Oral
  • Nasal
  • Injectables
  • Others
• By Drug Type
  • Small Molecule
  • Biologics
  • Cell & Gene Therapy
  • Others
• By Technology
  • Connected
    • Wi-Fi
    • Bluetooth
    • Others
  • Traditional
• By Application
  • Oncology
  • Neurology
  • Diabetes
  • Infectious Disease
  • Others
• By End-User
  • Hospitals
  • Specialty Clinics
  • Others

Table Of Contents

1. Executive Summary

2. Market Snapshot

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. Business Landscape

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

3.4. Porter's Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations

3.7. Strategic Recommendations

4. Technological Outlook

4.1. Product Pipeline

5. Canada Drug Delivery Market By Device Type (2020-2030)

5.1. Introduction

5.2. Inhalers

5.3. Autoinjectors

5.4. Infusion Pumps

5.5. Patches

5.6. Others

6. Canada Drug Delivery Market By Mode of Administration (2020-2030)

6.1. Introduction

6.2. Oral

6.3. Nasal

6.4. Injectables

6.5. Others

7. Canada Drug Delivery Market By Drug Type (2020-2030)

7.1. Introduction

7.2. Small Molecule

7.3. Biologics

7.4. Cell & Gene Therapy

7.5. Others

8. Canada Drug Delivery Market By Technology (2020-2030)

8.1. Introduction

8.2. Connected

8.2.1. Wi-Fi

8.2.2. Bluetooth

8.2.3. Others

8.3. Traditional

9. Canada Drug Delivery Market By Application (2020-2030)

9.1. Introduction

9.2. Oncology

9.3. Neurology

9.4. Diabetes

9.5. Infectious Disease

9.6. Others

10. Canada Drug Delivery Market By End-User (2020-2030)

10.1. Introduction

10.2. Hospitals

10.3. Specialty Clinics

10.4. Others

11. Competitive Environment and Analysis

11.1. Major Players and Strategy Analysis

11.2. Market Share Analysis

11.3. Mergers, Acquisitions, Agreements, and Collaborations

11.4. Competitive Dashboard

12. Company Profiles

12.1. Medtronic plc

12.2. AstraZeneca

12.3. Becton, Dickinson and Company

12.4. Boston Scientific Corporation

12.5. Johnson & Johnson

12.6. Apotex, Inc.

12.7. Insulet Corporation

12.8. NurExone Biologic Inc.

12.9. Rapid Dose Therapeutics Corp.

12.10. BioNxt Solutions Inc.

13. Research Methodology

List of Figures

List of Tables

Companies Profiled

Medtronic plc

AstraZeneca

Becton, Dickinson and Company

Boston Scientific Corporation

Johnson & Johnson

Apotex, Inc.

Insulet Corporation

NurExone Biologic Inc.

Rapid Dose Therapeutics Corp.

BioNxt Solutions Inc.    

Related Reports